NEW YORK, Jan. 10, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Agile Therapeutics, Inc. (“Agile Therapeutics”) (NASDAQ:AGRX) between March 9, 2016 and January 3, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/agile-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its “Secure” Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.
On January 3, 2017, Agile Therapeutics reported “positive top-line results” for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.
If you suffered a loss in Agile Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



